CX 621

Drug Profile

CX 621

Alternative Names: CX621

Latest Information Update: 04 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TiGenix
  • Class Anti-inflammatories; Stem cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 20 Aug 2013 CX 621 is available for licensing as of 20 Aug 2013. www.tigenix.com
  • 02 Jul 2012 Final adverse events data from a phase I trial in healthy volunteers released by TiGenix
  • 02 Jul 2012 TiGenix completes a phase I trial in healthy volunteers in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top